Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a Buy.
Platinum-resistant ovarian cancer (PROC) remains one of the most treatment-refractory malignancies, with a median overall survival (OS) of less than 12 months. Despite initial response to front-line ...
Pharmaceutical Technology on MSN
JPM26: MSD homes in on derisking strategy amid Keytruda patent cliff
MSD awaits 20 potential launches and 80 late-stage readouts across its pipeline, which it believes will double $35bn projected consensus 2028 Keytruda sales.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results